Pemetrexed in the treatment of selected solid tumors

被引：9

作者：

Adjei, AA

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

[2] Mayo Clin, Div Oncol, Rochester, MN USA

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 02期

关键词：

D O I：

10.1053/sonc.2002.30758

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：50 / 53

页数：4

共 18 条

[1] Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors [J].

Adjei, AA ;

Erlichman, C ;

Sloan, JA ;

Reid, JM ;

Pitot, HC ;

Goldberg, RM ;

Peethambaram, P ;

Atherton, P ;

Hanson, LJ ;

Alberts, SR ;

Jett, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1748-1757

[2] Pemetrexed: A multitargeted antifolate agent with promising activity in solid tumors [J].

Adjei, AA .

ANNALS OF ONCOLOGY, 2000, 11 (10) :1335-1341

[3] MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin [J].

Calvert, AH ;

Hughes, AN ;

Calvert, PM ;

Plummer, RE ;

Highley, MS .

EUROPEAN JOURNAL OF CANCER, 1999, 35 :S285-S286

[4]

CALVERT AH, 1998, BRIT J CANCER, V3, P34

[5]

GOEDHALS L, 1998, ANN ONCOL, V9, P339

[6]

GREM JL, 1990, CANC CHEMOTHERAPY PR, P180

[7]

GRINDEY G B, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P411

[8]

O'Dwyer PJ, 1999, SEMIN ONCOL, V26, P99

[9]

PAZARES L, 1998, P AN M AM SOC CLIN, V17, pA339

[10]

Pivot X, 1999, P AN M AM SOC CLIN, V18, p397a

← 1 2 →